2005 DRAFTING REQUEST

Senate Amendment (SA-SB288)

Received: 10/17/2005					Received By: pkahler		
Wanted: Soon					Identical to LRB:		
For: Cathy Stepp (608) 266-1832					By/Representing: Jay Risch		
This file may be shown to any legislator: NO					Drafter: pkahler		
May Contact:					Addl. Drafters:		
Subject: Insurance - health					Extra Copies:		
Submit	via email: YES						
Requester's email: Sen.Stepp@legis.state.wi.us							
Carbon	copy (CC:) to:						
Pre To	pic:						· · · · · · · · · · · · · · · · · · ·
No spec	ific pre topic gi	ven					
Topic:							
Approva	al of cancer clin	ical trials					
Instruc	tions:						
See Atta	ached						
Draftin	g History:	***************************************					
Vers.	Drafted	Reviewed	Typed	Proofed	Submitted	Jacketed	Required
/?	pkahler 10/17/2005	wjackson 10/17/2005					
/1			rschluet 10/17/20	05	mbarman 10/17/2005	mbarman 10/17/2005	
FE Sent	For:						

<END>

2005 DRAFTING REQUEST

Senate Amendment (SA-SB288)

Received: 10/17/2005 Received By: pkahler

Wanted: **Soon** Identical to LRB:

For: Cathy Stepp (608) 266-1832 By/Representing: Jay Risch

This file may be shown to any legislator: **NO**Drafter: **pkahler**

May Contact: Addl. Drafters:

Subject: Insurance - health Extra Copies:

Submit via email: YES

Requester's email: Sen.Stepp@legis.state.wi.us

Carbon copy (CC:) to:

Pre Topic:

No specific pre topic given

Topic:

Approval of cancer clinical trials

Instructions:

See Attached

Drafting History:

<u>Vers.</u> <u>Drafted</u> <u>Reviewed</u> <u>Typed</u> <u>Proofed</u> <u>Submitted</u> <u>Jacketed</u> <u>Required</u>

<END>

FE Sent For:

Kahler, Pam

From:

Risch, Jay

Sent:

Friday, October 14, 2005 4:41 PM

To:

Kahler, Pam

Cc:

Bruhn, Mike; 'la.maroney@hosp.wisc.edu'

Subject:

SB 288 amendments

Importance: High

Hi Pam,

Amendment 1. We're just leaving LRBa1126/1 (out-of-network costs) alone for now.

Amendment 2. Please add the "therapeutic intent" language on page 2, section A, items 1-3 from the link below. Please do <u>not</u> add anything about the 1-7 "desirable characteristics" language found right after the therapeutic intent language. I will return the stripes of LRBa1125/1 to you.

Amendment 3 (which doesn't exist yet): Please remove the reference to institutional review boards on page 4 lines 19 thru 21of SB 288.

Thanks! - Jay

From: Maroney Lisa A. [mailto:la.maroney@hosp.wisc.edu]

Sent: Friday, October 14, 2005 1:10 PM

To: Risch, Jay; osborne@hamilton-consulting.com; pmerline@tds.net; michael.heifetz@deancare.com; mmettner@broydrick.com; Sen.Roessler; Stegall, Jennifer; Bruhn, Mike; Catherine.Peters@cancer.org

Cc: Stewart James A; Wegenke Jane A; Wilding George; Pelatzke Sue

Subject: Compromise **Importance:** High

Greetings:

Our side has conferred on the 3 issues discussed at the meeting yesterday and accept nearly all of the changes requested by the two health plan groups.

- 1. **Out of network**. We are fine with the amendment as drafted, but because there now seems to be a possible difference of opinion between the two health plan groups, that needs to be worked out between them and hopefully quite quickly.
- 2. **New Medicare Language**. **We Accept in Part**. http://www.cms.hhs.gov/pf/printpage.asp? ref=http://63.241.27.79/manuals/06_cim/ci30.asp?#_1

I have attached the Medicare language link. On Page 2, Section A, 1-3 we are fine with having that drafted. That is really the heart of the therapeutic intent. Some of us believe that this is not needed because it's already explained in the bill. For example, of course this bill only applies to people with cancer as referenced in #3, but we hear the other side's concerns, so we are fine with adding that language.

We believe that items 1-7 would be difficult to draft. For example "Clinical trials also should have the following <u>desirable characteristics</u>". We believe much of what is in 1-7 is covered by the approving bodies or is already covered in the bill. Please let us know if there is something in 1-7 that you absolutely must have and please explain why it's needed and why you don't think it's already covered in the bill.

3. IRB. We accept. We are fine with removing the IRB reference on Page 4, line 19.

As you can see, we have agreed to nearly every change requested. We see absolutely no reason why the October 20 executive action needs to be further delayed. If WALHI members need to see LRB drafted language before they can decide then that should have been stated at our very first meeting on Sept. 13. Everyone has had the Medicare language since 9-13. I hope that items 2 and 3 can be put into drafting. Thanks.

Lisa Maroney UW-Madison, Health Sciences State Relations 635 Science Drive, Suite 150 Madison, WI 53711 (608)265-1653 (608)263-6394 fax



State of Misconsin 2005 - 2006 LEGISLATURE



PRELIMINARY DRAFT - NOT READY FOR INTRODUCTION SENATE AMENDMENT, TO 2005 SENATE BILL 288

Drote of

1 At the locations indicated, amend the bill as follows:

 $\sqrt{1}$. Page 4, line 19: delete lines 19 to 21.

3 (END)

This amendment removes approval of concer divided trials by institutional review boardso

71K

DRAFTER'S NOTE FROM THE LEGISLATIVE REFERENCE BUREAU

LRBa1165/1dn PJK:wlj:rs

October 17, 2005

This amendment removes approval of cancer clinical trials by institutional review boards.

Pamela J. Kahler Senior Legislative Attorney Phone: (608) 266–2682

E-mail: pam.kahler@legis.state.wi.us